In a melanoma xenograft mouse model, MRT-92 suppressed tumor growth at a systemic dose of 15 mg/Kg and significantly decreased GLI1 expression in tumor lesions, demonstrating efficient inhibition of HH signaling in vivo and providing the first evidence of anticancer therapeutic efficacy [112]. Here, GLI1 is linked to melanoma.